State of Alaska Department of Revenue Decreases Stake in Hologic, Inc. (NASDAQ:HOLX)

State of Alaska Department of Revenue cut its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 168,704 shares of the medical equipment provider's stock after selling 20,525 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.07% of Hologic worth $12,161,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic in the third quarter valued at approximately $25,000. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment increased its position in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares in the last quarter. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 416 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company's stock.

Hologic Trading Up 0.5 %

Shares of Hologic stock traded up $0.35 during trading hours on Monday, hitting $64.93. The company's stock had a trading volume of 1,819,329 shares, compared to its average volume of 2,557,376. Hologic, Inc. has a twelve month low of $63.62 and a twelve month high of $84.67. The firm has a fifty day moving average of $72.33 and a 200-day moving average of $77.76. The stock has a market cap of $14.66 billion, a price-to-earnings ratio of 20.52, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of recent analyst reports. Royal Bank of Canada cut their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday. JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Stephens reiterated an "overweight" rating and set a $84.00 price target on shares of Hologic in a research report on Thursday. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday. Finally, Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target for the company. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Hologic presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.